Let's Connect
Behavioral HealthNews

Ketamine drugmakers seek FDA approval as providers raise concerns: 5 things to know

Ella Ruder | October 21, 2026

More than a dozen companies are racing to win FDA approval for ketamine-based mental health treatments. Providers warn that one company’s bid could sharply raise the cost of the generic drug, while most of the new products are designed to skip the talk therapy many clinicians consider essential, The New York Times reported Oct. 20. The companies are developing new formulations and combinations of ketamine, a generic anesthetic increasingly used off-label for depression and other mental health conditions. Johnson & Johnson’s Spravato, a ketamine-like nasal spray, is the only FDA-approved… Originally published in Becker’s Hospital Review. Read More

Comments are closed.

Recent Posts

Apogem Capital Leads Minority Investment in Family Care Center

Laura Lovett | October 21, 2026

Do Psychedelics Need a Rebrand Before Their Approval for Mental Health?

Ashleigh Hollowell | October 21, 2026

Virginia mental health provider to settle Medicaid billing allegations for $1.8M

Ella Ruder | October 21, 2026

Covenant Health taps behavioral health VP

Ella Ruder | October 21, 2026

Ketamine drugmakers seek FDA approval as providers raise concerns: 5 things to know

Ella Ruder | October 21, 2026

Topics

Integrated Psychiatric Consultants

Office Hours:
Mon-Fri, 9 a.m. - 5 p.m. CT

Follow us

Reach out today.

Integrated Psychiatric Consultants (IPC) is committed to protecting and respecting your privacy. Our team will use the information collected here solely to serve your needs and notify you about relevant services. To consent, please check the box above and submit this form.

Please note, this consent applies to all forms of communications, including SMS. If you have provided a mobile phone number above, you agree to receiving SMS messages from IPC. You may unsubscribe at any time. Message frequency varies. Messaging and data rates may apply. Reply STOP to cancel. For more information, please review our Privacy Policy.